热门资讯> 正文
Alcon收购Aurion Biotech的多数股权
2025-03-27 04:55
- Alcon (ALC) said on Wednesday it has acquired a majority interest in Aurion Biotech, a company into developing advanced cell therapies to treat eye diseases.
- Aurion will continue to operate independently, with full support from Alcon to advance its lead cell therapy candidate, AURN001, into Phase 3 clinical trials in late 2025 for treating corneal edema caused by corneal endothelial disease.
- Through this partnership, Aurion will benefit from Alcon’s expertise in R&D, regulatory affairs, ophthalmic medicine, and commercialization.
- Alongside the acquisition, Aurion’s Board has appointed Arnaud Lacoste, formerly Chief Scientific Officer, as the company’s new CEO, effective immediately.
More on Alcon Inc.
- Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript
- Alcon Inc. 2024 Q4 - Results - Earnings Call Presentation
- Alcon: An Eyecare Leader With Strong Profit Margins, But Overheated Valuation
- Alcon upgraded at BofA Securities to Buy on earnings growth potential
- Alcon agrees to acquire LENSAR for $14.00 per share
推荐文章
美股机会日报 | 金价再创新高！黄金股普涨，哈莫尼黄金涨超4%；百度涨超7%
新股暗盘 | 大行科工大涨100%！中签一手赚4950港元
新股申购 | “全球激光雷达龙头”禾赛-W正在招股！一手入场费4605.99港元
华盛早报 | 大动作！特斯拉AI芯片+人型机器人，马斯克发声！禾赛今日招股；恒指成份股调整今日生效
港股周报丨疯狂扫货！北水年内净流入港股超万亿港元；创新药概念狂飙，三生制药周涨超22%
美股机会日报 | 8月非农大幅低于预期！纳指期货短线拉涨约0.7%；特斯拉盘前涨近2%
一周财经日历 | 事关降息！中美5月CPI、PPI重磅出炉！新股“超购王”大行科工下周上市
高盛：降新鸿基地产目标价至96港元 评级“买入”
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
